Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01495221 · ClinicalTrials.gov registry record · Phase 4
To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD
A Phase 4 study of AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy), sponsored by Vitreous -Retina- Macula Consultants of New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01495221 is a Phase 4 study of AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy) that has completed, run by Vitreous -Retina- Macula Consultants of New York. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01495221, a Phase 4 study of AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy), has completed, sponsored by Vitreous -Retina- Macula Consultants of New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label study to evaluate intravitreally administered 2.0 mg intravitreal aflibercept injection in patients who have been previously treated for AMD and have persistent or recurrent fluid despite monthly intravitreal anti-VEGF therapy.
Conditions Studied
Interventions
- DRUG Alfilbercept
Study Locations (1)
New York
- Vitreous Retina Macula Consultants of New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01495221
The ClinicalTrials.gov registry entry for NCT01495221 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vitreous -Retina- Macula Consultants of New York, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy) appearing as the primary indexed condition, and to 1 intervention - of which Alfilbercept is the first listed.
NCT01495221 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01495221 about?
NCT01495221 is a clinical study titled "To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD". This is an open label study to evaluate intravitreally administered 2.0 mg intravitreal aflibercept injection in patients who have been previously treated for AMD and have persistent or recurrent fluid despite monthly intravitreal anti-VEGF therapy.
What is the current status of trial NCT01495221?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2011-12. Estimated completion is 2013-03.
What conditions does trial NCT01495221 study?
This clinical trial studies the following conditions: AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy).
What interventions are being tested in trial NCT01495221?
The interventions under investigation include: Alfilbercept (DRUG).
Who is sponsoring clinical trial NCT01495221?
This trial is sponsored by Vitreous -Retina- Macula Consultants of New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01495221 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.